The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Still’s Disease Treatment-Global Market Insights and Sales Trends 2025
Synopsis
Still’s disease is a rare rheumatic condition. This condition is characterized by biological and clinical symptoms such as high spiking fever, joint swelling, muscle pain, sore throat, increased number of white cells (leukocytes, especially neutrophils), and biological hepatitis. Treatment for still’s disease can be classified into 2 categories, namely symptomatic treatments and effective therapies. Symptomatic treatments can be initiated immediately, even when the diagnosis has not been established whereas, effective therapies are designed to treat the condition more efficiently to eradicate the symptoms of the disease.
The global Still’s Disease Treatment market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Still’s Disease Treatment in various end use industries. The expanding demands from the Retail Pharmacies, Hospital Pharmacies and Online Pharmacies,, are propelling Still’s Disease Treatment market. Corticosteroids, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Tocilizumab segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Still’s Disease Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Still’s Disease Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Still’s Disease Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Still’s Disease Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Still’s Disease Treatment covered in this report include AB2 Bio Ltd, Novartis AG, F. Hoffmann-La Roche Ltd, Swedish Orphan Biovitrum AB, Jubilant, Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd, Viatris and Horizon Therapeutics plc, etc.
The global Still’s Disease Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
AB2 Bio Ltd
Novartis AG
F. Hoffmann-La Roche Ltd
Swedish Orphan Biovitrum AB
Jubilant
Hikma Pharmaceuticals PLC
Teva Pharmaceutical Industries Ltd
Viatris
Horizon Therapeutics plc
Sun Pharmaceutical Industries Ltd
Zydus Cadila
Amneal Pharmaceuticals LLC
Dr Reddy's Laboratories Ltd
Fresenius Kabi AG
Global Still’s Disease Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Still’s Disease Treatment market, Segment by Type:
Corticosteroids
Tocilizumab
Canakinumab
Anakinra
Others
Global Still’s Disease Treatment market, by Application
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Still’s Disease Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Still’s disease is a rare rheumatic condition. This condition is characterized by biological and clinical symptoms such as high spiking fever, joint swelling, muscle pain, sore throat, increased number of white cells (leukocytes, especially neutrophils), and biological hepatitis. Treatment for still’s disease can be classified into 2 categories, namely symptomatic treatments and effective therapies. Symptomatic treatments can be initiated immediately, even when the diagnosis has not been established whereas, effective therapies are designed to treat the condition more efficiently to eradicate the symptoms of the disease.
The global Still’s Disease Treatment market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Still’s Disease Treatment in various end use industries. The expanding demands from the Retail Pharmacies, Hospital Pharmacies and Online Pharmacies,, are propelling Still’s Disease Treatment market. Corticosteroids, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Tocilizumab segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Still’s Disease Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Still’s Disease Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Still’s Disease Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Still’s Disease Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Still’s Disease Treatment covered in this report include AB2 Bio Ltd, Novartis AG, F. Hoffmann-La Roche Ltd, Swedish Orphan Biovitrum AB, Jubilant, Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd, Viatris and Horizon Therapeutics plc, etc.
The global Still’s Disease Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
AB2 Bio Ltd
Novartis AG
F. Hoffmann-La Roche Ltd
Swedish Orphan Biovitrum AB
Jubilant
Hikma Pharmaceuticals PLC
Teva Pharmaceutical Industries Ltd
Viatris
Horizon Therapeutics plc
Sun Pharmaceutical Industries Ltd
Zydus Cadila
Amneal Pharmaceuticals LLC
Dr Reddy's Laboratories Ltd
Fresenius Kabi AG
Global Still’s Disease Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Still’s Disease Treatment market, Segment by Type:
Corticosteroids
Tocilizumab
Canakinumab
Anakinra
Others
Global Still’s Disease Treatment market, by Application
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Still’s Disease Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Still’s Disease Treatment
1.1 Still’s Disease Treatment Market Overview
1.1.1 Still’s Disease Treatment Product Scope
1.1.2 Still’s Disease Treatment Market Status and Outlook
1.2 Global Still’s Disease Treatment Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Still’s Disease Treatment Market Size by Region (2018-2029)
1.4 Global Still’s Disease Treatment Historic Market Size by Region (2018-2023)
1.5 Global Still’s Disease Treatment Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Still’s Disease Treatment Market Size (2018-2029)
1.6.1 North America Still’s Disease Treatment Market Size (2018-2029)
1.6.2 Europe Still’s Disease Treatment Market Size (2018-2029)
1.6.3 Asia-Pacific Still’s Disease Treatment Market Size (2018-2029)
1.6.4 Latin America Still’s Disease Treatment Market Size (2018-2029)
1.6.5 Middle East & Africa Still’s Disease Treatment Market Size (2018-2029)
2 Still’s Disease Treatment Market by Type
2.1 Introduction
2.1.1 Corticosteroids
2.1.2 Tocilizumab
2.1.3 Canakinumab
2.1.4 Anakinra
2.1.5 Others
2.2 Global Still’s Disease Treatment Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Still’s Disease Treatment Historic Market Size by Type (2018-2023)
2.2.2 Global Still’s Disease Treatment Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Still’s Disease Treatment Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Still’s Disease Treatment Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Still’s Disease Treatment Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Still’s Disease Treatment Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Still’s Disease Treatment Revenue Breakdown by Type (2018-2029)
3 Still’s Disease Treatment Market Overview by Application
3.1 Introduction
3.1.1 Retail Pharmacies
3.1.2 Hospital Pharmacies
3.1.3 Online Pharmacies
3.2 Global Still’s Disease Treatment Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Still’s Disease Treatment Historic Market Size by Application (2018-2023)
3.2.2 Global Still’s Disease Treatment Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Still’s Disease Treatment Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Still’s Disease Treatment Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Still’s Disease Treatment Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Still’s Disease Treatment Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Still’s Disease Treatment Revenue Breakdown by Application (2018-2029)
4 Still’s Disease Treatment Competition Analysis by Players
4.1 Global Still’s Disease Treatment Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Still’s Disease Treatment as of 2022)
4.3 Date of Key Players Enter into Still’s Disease Treatment Market
4.4 Global Top Players Still’s Disease Treatment Headquarters and Area Served
4.5 Key Players Still’s Disease Treatment Product Solution and Service
4.6 Competitive Status
4.6.1 Still’s Disease Treatment Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 AB2 Bio Ltd
5.1.1 AB2 Bio Ltd Profile
5.1.2 AB2 Bio Ltd Main Business
5.1.3 AB2 Bio Ltd Still’s Disease Treatment Products, Services and Solutions
5.1.4 AB2 Bio Ltd Still’s Disease Treatment Revenue (US$ Million) & (2018-2023)
5.1.5 AB2 Bio Ltd Recent Developments
5.2 Novartis AG
5.2.1 Novartis AG Profile
5.2.2 Novartis AG Main Business
5.2.3 Novartis AG Still’s Disease Treatment Products, Services and Solutions
5.2.4 Novartis AG Still’s Disease Treatment Revenue (US$ Million) & (2018-2023)
5.2.5 Novartis AG Recent Developments
5.3 F. Hoffmann-La Roche Ltd
5.3.1 F. Hoffmann-La Roche Ltd Profile
5.3.2 F. Hoffmann-La Roche Ltd Main Business
5.3.3 F. Hoffmann-La Roche Ltd Still’s Disease Treatment Products, Services and Solutions
5.3.4 F. Hoffmann-La Roche Ltd Still’s Disease Treatment Revenue (US$ Million) & (2018-2023)
5.3.5 Swedish Orphan Biovitrum AB Recent Developments
5.4 Swedish Orphan Biovitrum AB
5.4.1 Swedish Orphan Biovitrum AB Profile
5.4.2 Swedish Orphan Biovitrum AB Main Business
5.4.3 Swedish Orphan Biovitrum AB Still’s Disease Treatment Products, Services and Solutions
5.4.4 Swedish Orphan Biovitrum AB Still’s Disease Treatment Revenue (US$ Million) & (2018-2023)
5.4.5 Swedish Orphan Biovitrum AB Recent Developments
5.5 Jubilant
5.5.1 Jubilant Profile
5.5.2 Jubilant Main Business
5.5.3 Jubilant Still’s Disease Treatment Products, Services and Solutions
5.5.4 Jubilant Still’s Disease Treatment Revenue (US$ Million) & (2018-2023)
5.5.5 Jubilant Recent Developments
5.6 Hikma Pharmaceuticals PLC
5.6.1 Hikma Pharmaceuticals PLC Profile
5.6.2 Hikma Pharmaceuticals PLC Main Business
5.6.3 Hikma Pharmaceuticals PLC Still’s Disease Treatment Products, Services and Solutions
5.6.4 Hikma Pharmaceuticals PLC Still’s Disease Treatment Revenue (US$ Million) & (2018-2023)
5.6.5 Hikma Pharmaceuticals PLC Recent Developments
5.7 Teva Pharmaceutical Industries Ltd
5.7.1 Teva Pharmaceutical Industries Ltd Profile
5.7.2 Teva Pharmaceutical Industries Ltd Main Business
5.7.3 Teva Pharmaceutical Industries Ltd Still’s Disease Treatment Products, Services and Solutions
5.7.4 Teva Pharmaceutical Industries Ltd Still’s Disease Treatment Revenue (US$ Million) & (2018-2023)
5.7.5 Teva Pharmaceutical Industries Ltd Recent Developments
5.8 Viatris
5.8.1 Viatris Profile
5.8.2 Viatris Main Business
5.8.3 Viatris Still’s Disease Treatment Products, Services and Solutions
5.8.4 Viatris Still’s Disease Treatment Revenue (US$ Million) & (2018-2023)
5.8.5 Viatris Recent Developments
5.9 Horizon Therapeutics plc
5.9.1 Horizon Therapeutics plc Profile
5.9.2 Horizon Therapeutics plc Main Business
5.9.3 Horizon Therapeutics plc Still’s Disease Treatment Products, Services and Solutions
5.9.4 Horizon Therapeutics plc Still’s Disease Treatment Revenue (US$ Million) & (2018-2023)
5.9.5 Horizon Therapeutics plc Recent Developments
5.10 Sun Pharmaceutical Industries Ltd
5.10.1 Sun Pharmaceutical Industries Ltd Profile
5.10.2 Sun Pharmaceutical Industries Ltd Main Business
5.10.3 Sun Pharmaceutical Industries Ltd Still’s Disease Treatment Products, Services and Solutions
5.10.4 Sun Pharmaceutical Industries Ltd Still’s Disease Treatment Revenue (US$ Million) & (2018-2023)
5.10.5 Sun Pharmaceutical Industries Ltd Recent Developments
5.11 Zydus Cadila
5.11.1 Zydus Cadila Profile
5.11.2 Zydus Cadila Main Business
5.11.3 Zydus Cadila Still’s Disease Treatment Products, Services and Solutions
5.11.4 Zydus Cadila Still’s Disease Treatment Revenue (US$ Million) & (2018-2023)
5.11.5 Zydus Cadila Recent Developments
5.12 Amneal Pharmaceuticals LLC
5.12.1 Amneal Pharmaceuticals LLC Profile
5.12.2 Amneal Pharmaceuticals LLC Main Business
5.12.3 Amneal Pharmaceuticals LLC Still’s Disease Treatment Products, Services and Solutions
5.12.4 Amneal Pharmaceuticals LLC Still’s Disease Treatment Revenue (US$ Million) & (2018-2023)
5.12.5 Amneal Pharmaceuticals LLC Recent Developments
5.13 Dr Reddy's Laboratories Ltd
5.13.1 Dr Reddy's Laboratories Ltd Profile
5.13.2 Dr Reddy's Laboratories Ltd Main Business
5.13.3 Dr Reddy's Laboratories Ltd Still’s Disease Treatment Products, Services and Solutions
5.13.4 Dr Reddy's Laboratories Ltd Still’s Disease Treatment Revenue (US$ Million) & (2018-2023)
5.13.5 Dr Reddy's Laboratories Ltd Recent Developments
5.14 Fresenius Kabi AG
5.14.1 Fresenius Kabi AG Profile
5.14.2 Fresenius Kabi AG Main Business
5.14.3 Fresenius Kabi AG Still’s Disease Treatment Products, Services and Solutions
5.14.4 Fresenius Kabi AG Still’s Disease Treatment Revenue (US$ Million) & (2018-2023)
5.14.5 Fresenius Kabi AG Recent Developments
6 North America
6.1 North America Still’s Disease Treatment Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Still’s Disease Treatment Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Still’s Disease Treatment Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Still’s Disease Treatment Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Still’s Disease Treatment Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Still’s Disease Treatment Market Dynamics
11.1 Still’s Disease Treatment Industry Trends
11.2 Still’s Disease Treatment Market Drivers
11.3 Still’s Disease Treatment Market Challenges
11.4 Still’s Disease Treatment Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
